Novartis

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novartis and other ETFs, options, and stocks.

About NVS

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies.

CEO

Vasant Narasimhan

CEOVasant Narasimhan

Employees

75,267

Employees75,267

Headquarters

Basel, Basel-Stadt (Basle Town)

HeadquartersBasel, Basel-Stadt (Basle Town)

Founded

1996

Founded1996

Employees

75,267

Employees75,267

NVS Key Statistics

Market cap

306.97B

Market cap306.97B

Price-Earnings ratio

21.37

Price-Earnings ratio21.37

Dividend yield

2.04%

Dividend yield2.04%

Average volume

2.08M

Average volume2.08M

High today

$152.57

High today$152.57

Low today

$150.20

Low today$150.20

Open price

$151.43

Open price$151.43

Volume

1.66M

Volume1.66M

52 Week high

$170.46

52 Week high$170.46

52 Week low

$112.34

52 Week low$112.34

NVS News

Zacks 2d

Novartis' Rhapsido Meets Primary Goal in Phase III Skin Disorder Study - Zacks Investment Research

...

TipRanks 6d

Novartis announces Rhapsido met primary endpoints in RemIND trial

Novartis (NVS) presented data from the RemIND trial at the European Academy of Allergy and Clinical Immunology, EAACI, Congress showing that Rhapsido met its pr...

Seeking Alpha 6d

Kymera, Monte Rosa among gainers as Novartis inks deal for molecular glue drugs

An expanded deal between Novartis (NVS) and privately held Orionis Biosciences for molecular glue drugs on Thursday boosted shares of Monte Rosa Therapeutics (G...

Analyst ratings

50%

of 28 ratings

Buy

35.7%

Hold

50%

Sell

14.3%

More NVS News

Benzinga 7d

Novartis' $12 Billion Bet Pays Off With Encouraging Data From Rare Neuromuscular Disease Study

Trial Meets Endpoints FSHD affects an estimated 45,000 to 87,000 people across the U.S. and Europe and is characterized by progressive muscle weakness, pain, f...

TipRanks 7d

Novartis Del-brax Trial Hits Key Biomarker Goals in FSHD, Phase III Under Way

Novartis ( (NVS) ) has issued an update. On June 11, 2026, Novartis reported that the biomarker cohort of its FORTITUDE Phase I/II trial of delpacibart braxlos...

TipRanks 7d

Novartis Del-brax Data Bolster FSHD Outlook as Analyst Reiterates Buy and Maintains $135 Price Target

In a report released today, Thibault Boutherin from Morgan Stanley maintained a Buy rating on Novartis AG, with a price target of CHF135.00. Introducing TipRank...

TipRanks 7d

Novartis: Buy Rating Reiterated as Del-brax Data and Late-Stage Pipeline Support Unchanged CHF 140 Price Target

In a report released today, Sachin Jain from Bank of America Securities maintained a Buy rating on Novartis AG, with a price target of CHF140.00. Sachin Jain h...

TipRanks 7d

Novartis announces biomarker cohort in study of del-brax met primary endpoint

Novartis (NVS) announced that the biomarker cohort of the Fortitude Phase I/II study of del-brax met its primary and key secondary endpoints, with reductions in...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.